Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AIDS Vaccine's Low Efficacy Rate Makes Cmte. Skeptical About Phase III Potential

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA committee members express concern over vaccine's low CD8 cytotoxic T lymphocyte activity and lack of neutralizing antibody response in Phase II trial. Agency cites regulatory challenge associated with approving a vaccine that is not effective against U.S. sub-type of AIDS virus.

You may also be interested in...



Merck Research Labs Exec Joins VaxGen

Former Merck Research Labs Executive Director-Microbial Vaccine Research Kathrin Jansen, PhD, has been named senior VP-R&D and chief scientific officer at VaxGen, the company announced Oct. 19

Merck Research Labs Exec Joins VaxGen

Former Merck Research Labs Executive Director-Microbial Vaccine Research Kathrin Jansen, PhD, has been named senior VP-R&D and chief scientific officer at VaxGen, the company announced Oct. 19

AIDS Vaccine Efficacy May Not Transfer To U.S. Population, FDA Says

The U.S. Army is conducting a Phase III study in Thailand of a product that combines Sanofi-Aventis and VaxGen vaccines, briefing materials for Vaccines & Related Biological Products Advisory Committee’s Sept. 23 meeting state. However, FDA considers the trial to be a “proof of concept” study.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel